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Introduction
Only very few species will be suitable as organ
source for humans based solely on size and
function. The domestic pig seems to possess
many of the required characteristics with regard
to organ size and efficiency (7).  However, one
major problem by using pig organs is the exis-
tence of terminal α-1,3-galactosyltransferase
(abbreviation: the α-Gal epitope) on its cell sur-
faces. Primates including humans do not pos-
sess this epitope, they do have natural antibod-
ies against the α-Gal epitope, and following
transfer of an organ from for example a pig this
will lead to the so-called hyperacute rejection
(HAR; 5). In order to use pigs as donors it is
therefore mandatory to use donors where the
Gal-epitope has been "knocked-out", or where
genes coding for human compliments have
been added to the genome (2, 3) or both.  Pro-
duction of transgenic pigs is therefore probably
the most important part of producing organs for
xenotransplantation, and in the following some
embryo-technological aspects and Danish atti-
tudes towards this new and emerging field of re-
search and clinical application will be ad-
dressed.  Several excellent reviews are available
on this issue (15).
Embryo-technological aspects
The first transgenic pigs were produced in 1985
by injecting several hundred copies of the hu-
man growth hormone gene into one of the
pronuclei of newly fertilized pig eggs (8), and
this technique is still viable and being used in
many laboratories (13, 19, 20, 21). The tech-
nique was also used to produce pigs transgenic
with respect to the human complement system,
CD55 and CD59 (2, 16), H transferase (3) and
human decay accelerating factor (14). The av-
erage success rate following pronuclear injec-
tion is still below 1%, and production of mosaic
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embryos is a pronounced problem (12, 18)
which does not occur after transfection of so-
matic cells used for subsequent somatic cell nu-
clear transfer (SCNT; 17). The pronuclear in-
jection technique will, however, -never allow
homologous recombination to remove the α-
Gal epitope gene i.e., to "knock-out" one or two
alleles of this single gene (5).  An ample avail-
ability of stem cells, genetic modification of
these, and SCNT followed by embryo trans-
plantation of one-cell zygotes and delivery of
normal live born offspring, are the only ways to
obtaining knock-out pigs from which organs
may be transplanted without eliciting the HAR.
Much effort has consequently been devoted to
this attractive alternative. Recently Lai et al.
(10) reported that they had produced a-1,3-
galactosyltransferase knock-out pigs by SCNT.
In the same year PPL Therapeutics announced
that they had produced piglets, which had dis-
played a knock-out of one allele coding for the
α-Gal epitope. The reports quoted above had
only one allele knocked-out, but then in 2002, it
was reported that transgenic pigs with both al-
leles silenced had been born at the PPL Thera-
peutics premises (cited in: Vet Science Tomor-
row, August 27, 2002). This step has brought
xenotransplantation even closer to reality, and
one may now envisage that it is possible to pro-
duce herds of pigs from where organs can be
used for humans.
There are, however, a number of obstacles, one
being the very low efficiency of the embryo-
technology. The SCNT technique combined
with transgenesis yields egg cleavage rates fol-
lowing fusion and activation of 60-70% (9, 11),
blastocyst rates of about 10% (9, 11), mean
number of nuclei per blastocyst of about 25-30
(9, 11), but very poor production rates of cloned
transgenic animals: only 14 transgenic piglets
of 338 embryos transferred to 3 recipients (10)
and one transgenic piglet of 150 transferred
embryos (11). This is less than 0.03% pig born
per transplanted cloned transgenic embryo. In
addition, the offspring may have a higher inci-
dence of malformations, such as deformations
of the extremities (10). Recent Danish data us-
ing a zona free manipulation technique to per-
form somatic nuclear transfer showed that 85%
were successfully fused and survived activa-
tion, and that the total blastocyst rate was ap-
proximately 5% with the blastocysts containing
an average of about 35 cells. It should be em-
phasized that these were non-transgenic (1).
The embryo-technological aspects of manufac-
turing SCNT and cloned embryos is far from
being perfect, but the progress in SCNT in
combination with the advancement at the
molecular biology front, and in particular in ho-
mologous recombination, will undoubtedly
bring us very rapidly forward with the final
goal, i.e. to produce offspring possessing the
genotypes which render them suitable as organ-
donors.  
Danish attitudes
The Danish ad hoc Committee on Gene Tech-
nology was set up as a consequence of a debate
in the Danish Parliament (Folketinget) in Jan-
uary 2001, and one of the issues to be discussed
was xenotransplantation. The report by the
committee was published on October 24th,
2002. In the following, some points from this
report will be presented (4). 
Xenotransplantation would in principle provide
an unlimited number of organs such as kidneys,
hearts and livers for transplantation to humans.
Cells from genetically modified animals may be
used to repair degenerated or dead cells in dif-
ferent parts of the human body. There are, how-
ever, a number of problems inherent to imple-
mentation of this technology. As mentioned
earlier there is the problem of the hyperacute re-
action (HAR), which might be overcome by use
of organs from knock-out pigs. But other rejec-
tions will occur, and it means that the individual
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should be on immunosuppressive medicine for
the rest of her or his life. Of even greater soci-
etal concern is the risk for spreading diseases
between man and animals and thus creating
new epidemics and zoonosis of already known
or entirely new diseases. The porcine endogene
retrovirus (PERV) is of major concern as it
replicates in the genome. Recent data from
mice have clearly shown that it is a real problem
particularly in immunosuppressed animals.
Prion mediated diseases are also in focus. Due
to these precautions it is very likely that the per-
son receiving the organ and the family would
stay in solitary confinement for a certain period
of time. They may also have to submit to travel
restrictions to certain international destina-
tions, from where diseases important, not only
for humans but also for animals, may be im-
ported into Denmark and subsequently be dis-
seminated in the domestic human and/or animal
populations. 
Thus rejection and diseases are major concerns,
but in addition the problems of functionality of
pig organs in humans have been addressed. The
literature is limited in this field, but there are
obvious anatomical and functional differences
between human and pig organs. Just to mention
a few: cardiac output, stroke volume, heart
valves, blood viscosity, posture (upright versus
horizontal) affecting inhalation and exhalation,
liver perfusion, molecular differences regarding
hormones, receptors and enzymes of the kidney
and liver (6, 7).  It is virtually unknown how, for
example, a pig heart will function in a human
body providing it is not rejected. And how will
the blood pressure be maintained following
transplantation of a pig kidney?  
The ethical issues have been divided in two cat-
egories; on one hand the human ethical aspects,
and on the other the animal ethical problems. 
In the human ethical field it is on one hand the
ability to replace human organ by xeno- rather
than heterotransplantation and, thus, the ability
to cure terminally ill people. This is of para-
mount importance. On the other hand, is the in-
dividual integrity being equally important.
Would xenotransplantation mean that the bor-
derline between man and animals is crossed?
Another important issue is the respect for the
autonomy of the patient. It is likely that all pa-
tients receiving an animal organ, will be under
public surveillance and control, and is that de-
sirable? What about extended quarantine? And
must the family be submitted to the same regu-
lations?   
It is obviously also very important that harm is
not inflicted upon others, and preventing that
will really require strict regulations from the in-
volved authorities. 
Animal ethical considerations must also be
taken into account. It is known that SCNT com-
bined with transgenesis may elicit unwanted
side effects (malformations, poor survival)
which in turn cause suffering and pain. All nec-
essary precautions must be taken to avoid this,
and one should weight these against the bene-
fits. Rearing of the animals may also be fairly
restricted leading to stressful conditions. It has
been suspected that pigs transgenic for the a-
Gal epitope, may have certain subtle eye dis-
eases. 
It should, finally, be mentioned that implemen-
tation of xenotransplantation probably will be
expensive and thus, place further stress on a
health system already strained from constant
pressure, to implement new and advanced tech-
nologies. 
Concluding remarks
Whether xenotransplantation will ever be a re-
alistic alternative to heterotransplantation, is
still an open question. It will require not only
advanced basic research, but also a great deal of
clinical investigations, and this will undoubt-
edly cause some degree of suffering in the ini-
tial phase. The recent availability of knock-out
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pigs and the attenuation this represents of one
of the most unwanted side effects, namely
HAR, has given some hope to many patients ur-
gently in need for a new organ. 
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Sammendrag
Xenotransplantation: bioteknologiske aspekter og
danske holdninger.
Transplantation af organer fra vore husdyr forudsæt-
ter, at de er genetisk modificeret (transgene) specielt
med hensyn til den såkaldte α-Gal epitop, visse hu-
mane komplementfaktorer  (CD55 og CD59) og/ el-
ler H-transferase. Fremstilling af transgene grise er
en kompliceret proces med fortsat lav succes. For-
kerne injektioner giver under 1% afkom og kombina-
tionen af kloning og genetisk modifikation er endnu
mindre effektiv (0,03%). Sidstnævnte teknik er imid-
lertid en forudsætning for, at man kan fremstille
knock-out grise, hvor generne, som koder for α-Gal
epitopen, er gjort tavse. Disse aspekter omtales i ar-
tiklen. Det danske Genteknologiudvalg, som blev
nedsat af Ministeriet for Videnskab, Teknologi og
Udvikling afleverede sin rapport den 24. oktober
2002 og en række af dette udvalgs konklusioner om-
tales i den sidste del af artiklen. Herunder afstød-
nings- og smitte problematikken, human etiske og
dyreetiske overvejelser samt hvilke myndigheder,
som har ansvar for at de forskellige anbefalinger
føres videre i systemet. Rapporten kan erhverves på
www.videnskabsministeriet.dk
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